iMOL Announces Acceptance into JLABS Incubator NetworkIssuing time:2026-02-09 11:48 Strategic Membership Unlocks Access to Global Innovation Resources and Collaborative Ecosystem
Singapore, February 2026 – iMOL, a fast-growing AI-driven tech company, announced that it has been accepted into Johnson & Johnson’s global incubator network as a JLABS Singapore member company. This marks iMOL's first international strategic membership since its founding. The membership establishes a framework for iMOL to leverage specialized resources to advance its growth objectives.
Strategic Value of the Agreement JLABS is the largest global network of open innovation ecosystems, enabling and empowering emerging companies with the knowledge, experience, partnerships, and venture connections across a broad healthcare spectrum including pharmaceutical and medical technology sectors. "We are delighted to join the JLABS community,” said Jielong Zhou, Chief Executive Officer of iMOL. “iMOL has always focused on not only technological innovation but also the connections with the innovation ecosystem. We look forward to leveraging our membership to help advance our research and development initiatives and explore new pathways for innovation and collaboration worldwide. We will remain committed to delivering more advanced AI-driven drug discovery tools to pharmaceutical companies and research institutions, bringing innovative technology achievements to benefit patients worldwide." About iMOL
iMOL is an AI-driven company focused on novel drug discovery, and became a JLABS Singapore member company in 2026.
Leveraging industry expertise, breakthroughs in AI technology, in-depth data governance capabilities, and robust software and hardware capabilities, the company has developed a multimodal AI 3D generation model focused on small molecules. Based on the GPT/Transformer architecture and integrated with geometric deep learning technology, this model can accurately generate molecules that match the targets and extend to multiple modalities. In addition, the company can provide customized solutions for the industry.
Currently, pharmaceutical enterprises and research institutions worldwide utilize this AI platform for early-stage R&D activities.
Media Inquiries: press@iMOLx.com
For more information, please visit the iMOL official website. Statement: This article is original to our website.For republication, please credit the source with a link: https://www.imolx.com/sys-nd/37.html
|